Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AN2 Therapeutics, Inc. - Common Stock
(NQ:
ANTX
)
1.040
-0.010 (-0.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AN2 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Today 5:24 EDT
Via
Benzinga
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
August 16, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Citizens And 2 Other Penny Stocks Insiders Are Buying
August 15, 2024
Via
Benzinga
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
August 09, 2024
AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial.
Via
InvestorPlace
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
August 13, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
August 13, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
August 09, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
August 09, 2024
Via
Benzinga
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
August 09, 2024
AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung disease. The study showed similar sputum culture conversion rates between...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 09, 2024
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!
Via
InvestorPlace
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
August 08, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
June 14, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
May 14, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 04, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
March 28, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
February 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
February 12, 2024
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 12, 2024
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...
Via
Benzinga
US Stocks Mixed; Trimble Issues Weak Outlook
February 12, 2024
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
February 12, 2024
AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024.
Via
Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
February 12, 2024
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.